Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec 20:2011:658083.
doi: 10.4061/2011/658083.

Limitations of animal models of Parkinson's disease

Affiliations

Limitations of animal models of Parkinson's disease

J A Potashkin et al. Parkinsons Dis. .

Abstract

Most cases of Parkinson's disease (PD) are sporadic. When choosing an animal model for idiopathic PD, one must consider the extent of similarity or divergence between the physiology, anatomy, behavior, and regulation of gene expression between humans and the animal. Rodents and nonhuman primates are used most frequently in PD research because when a Parkinsonian state is induced, they mimic many aspects of idiopathic PD. These models have been useful in our understanding of the etiology of the disease and provide a means for testing new treatments. However, the current animal models often fall short in replicating the true pathophysiology occurring in idiopathic PD, and thus results from animal models often do not translate to the clinic. In this paper we will explain the limitations of animal models of PD and why their use is inappropriate for the study of some aspects of PD.

PubMed Disclaimer

References

    1. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39(6):889–909. - PubMed
    1. Meissner W, Hill MP, Tison F, Gross CE, Bezard E. Neuroprotective strategies for Parkinson’s disease: conceptual limits of animal models and clinical trials. Trends in Pharmacological Sciences. 2004;25(5):249–253. - PubMed
    1. Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson’s disease. Journal of Neuroscience. 2001;21(17):6853–6861. - PMC - PubMed
    1. Scheller D, Chan P, Li Q, et al. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson’s disease. Experimental Neurology. 2007;203(2):415–422. - PubMed
    1. Tenreiro S, Outeiro TF. Simple is good: yeast models of neurodegeneration. to appear in FEMS Yeast Research. - PubMed

LinkOut - more resources